{
  "title": "Staging Systems: Hematologic Cancer Staging (NHL, HL, Leukemia)",
  "category": "Clinical Assessment",
  "section": "Cancer Staging",
  "summary": "Comprehensive guide to staging systems for hematologic malignancies including lymphomas and leukemias.",
  "author": "OncoVISTA Team",
  "lastUpdated": "2023-10-20T00:00:00Z",
  "version": "1.1.0",
  "metadata": {
    "reviewStatus": "peer-reviewed",
    "readingTimeMinutes": 15,
    "targetAudience": ["Hematologists", "Oncologists", "Pathologists"]
  },
  "content": [
    {
      "type": "heading",
      "level": 1,
      "text": "Staging Systems"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Topic 6: Hematologic Cancer Staging (NHL, HL, Leukemia)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "1. Introduction"
    },
    {
      "type": "paragraph",
      "text": "Hematologic malignancies differ fundamentally from solid tumors in that they often present with systemic or diffuse disease rather than a localized mass. Staging in these diseases reflects lymphatic involvement, bone marrow infiltration, organ spread, and disease biology."
    },
    {
      "type": "paragraph",
      "text": "Key distinctions:"
    },
    {
      "type": "list",
      "items": [
        "Lymphomas use anatomic staging systems (Ann Arbor, Lugano).",
        "Leukemias rely on molecular and risk-based classifications, not anatomical staging.",
        "Imaging, PET/CT, and bone marrow assessment are essential components in most cases."
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "2. Hodgkin Lymphoma (HL)"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Staging: Lugano Classification (2014)"
    },
    {
      "type": "paragraph",
      "text": "An evolution of the Ann Arbor system with integrated PET-CT imaging."
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Single lymph node region or a single extranodal site (IE)"],
        ["II", "Two or more lymph node areas on the same side of the diaphragm (II) or with contiguous extranodal spread (IIE)"],
        ["II bulky", "Stage II with a bulky nodal mass (≥10 cm or >1/3 of chest diameter)"],
        ["III", "Lymph node regions on both sides of the diaphragm (± spleen = IIIS)"],
        ["IV", "Disseminated extralymphatic disease (e.g., liver, lungs, bone marrow)"]
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Modifiers:"
    },
    {
      "type": "list",
      "items": [
        "A: No B symptoms",
        "B: Presence of B symptoms (fever, weight loss, night sweats)",
        "E: Extranodal extension",
        "X: Bulky disease"
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Bone marrow biopsy is usually unnecessary if PET-CT is available and does not show marrow involvement."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Prognostic Tools"
    },
    {
      "type": "list",
      "items": [
        "IPS (International Prognostic Score) for advanced HL:",
        "  - Seven factors (e.g., low albumin, anemia, male sex, WBC >15,000)",
        "  - Score 0–1: 5-year OS ≥ 89%; Score 4–7: OS ≤ 61%",
        "Limited-stage HL uses unfavorable risk factors such as:",
        "  - High ESR, bulky disease, ≥3 node regions, age ≥50"
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "3. Non-Hodgkin Lymphoma (NHL)"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Staging: Lugano Classification"
    },
    {
      "type": "paragraph",
      "text": "Used for both indolent and aggressive NHL types."
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Single nodal group or a single extranodal site"],
        ["II", "≥2 nodal groups on the same side of the diaphragm"],
        ["III", "Nodes on both sides of the diaphragm or nodes + spleen involvement"],
        ["IV", "Disseminated extranodal disease (e.g., liver, bone marrow)"]
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Staging Workup"
    },
    {
      "type": "list",
      "items": [
        "PET-CT: For FDG-avid lymphomas (most aggressive NHLs)",
        "CT scan: For indolent, non-FDG-avid lymphomas (e.g., CLL/SLL, marginal zone lymphoma)",
        "Bone marrow biopsy: Usually required, unless PET shows marrow involvement"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Prognostic Models"
    },
    {
      "type": "list",
      "items": [
        "IPI (International Prognostic Index):",
        "  - Factors: Age >60, ECOG >1, Stage III/IV, LDH, extranodal disease",
        "FLIPI/m7-FLIPI: For follicular lymphoma, integrating clinical and molecular markers"
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Histology and biology (e.g., BCL2, MYC, TP53 mutations) often outweigh anatomic stage in prognostic value."
    },
    {
      "type": "heading",
      "level": 3,
      "text": "4. Leukemias"
    },
    {
      "type": "paragraph",
      "text": "Leukemias are not staged anatomically. They are instead classified using clinical features, cytogenetics, molecular mutations, and therapy response."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Acute Myeloid Leukemia (AML)"
    },
    {
      "type": "list",
      "items": [
        "ELN 2022 classification (European LeukemiaNet):",
        "  - Favorable: NPM1 mutation without FLT3-ITD, core-binding factor leukemias",
        "  - Intermediate: Normal karyotype, IDH1/2 mutations",
        "  - Adverse: TP53 mutation, complex karyotype, RUNX1 mutation",
        "Bone marrow blasts >20% define AML",
        "MRD status post-therapy increasingly guides prognosis"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Acute Lymphoblastic Leukemia (ALL)"
    },
    {
      "type": "list",
      "items": [
        "Prognostic variables:",
        "  - Age, WBC count, CNS/testicular involvement",
        "  - Cytogenetics (e.g., BCR-ABL, t(12;21))",
        "  - MRD clearance is the strongest predictor of relapse",
        "Pediatric ALL follows risk-adapted treatment protocols based on Day 8/29 MRD"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Chronic Lymphocytic Leukemia (CLL)"
    },
    {
      "type": "list",
      "items": [
        "Rai staging (USA):",
        "  - 0 (lymphocytosis only) → IV (thrombocytopenia)",
        "Binet staging (Europe):",
        "  - A (≤2 sites) → C (cytopenia)",
        "Molecular markers critical:",
        "  - del(17p)/TP53 mutations = poor prognosis",
        "  - IGHV mutation status = therapy selection",
        "MRD assessment post-therapy predicts time to progression"
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "5. Key Differences Summary Table"
    },
    {
      "type": "table",
      "headers": ["Feature", "HL/NHL", "Leukemia"],
      "rows": [
        ["Staging system", "Ann Arbor/Lugano", "Risk classification"],
        ["Imaging", "PET/CT standard", "Often not required"],
        ["Bone marrow", "Optional (HL) / common (NHL)", "Always involved"],
        ["MRD", "Not routinely used", "Essential for prognosis"],
        ["Genetic risk", "Less emphasized", "Central to prognosis and therapy"]
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "6. Summary"
    },
    {
      "type": "paragraph",
      "text": "Hematologic cancers require tailored staging systems. HL and NHL continue to use anatomical-based staging (Ann Arbor, Lugano), while leukemias rely entirely on biologic and molecular risk stratification. PET-CT and MRD have revolutionized staging accuracy, particularly in lymphoma and leukemia, respectively. Understanding both disease biology and staging nuance is essential for optimal patient management."
    }
  ]
}